Heidelberg Pharma secures a $115M royalty financing deal with HCRx for Zircaix™, a radiopharmaceutical PET agent for clear cell renal cancer diagnosis.
Heidelberg Pharma AG secures a royalty financing deal with HealthCare Royalty (HCRx) worth up to $115M based on future royalties from worldwide sales of Zircaix™, a radiopharmaceutical PET imaging agent for clear cell renal cancer diagnosis. The deal includes a $25M upfront payment, potential $75M upon FDA approval, and $15M for exceeding 2025 sales. Heidelberg licensed the antibody to Telix Pharmaceuticals Limited in 2017, with Phase III trials completed Q3 2022.
March 04, 2024
3 Articles